Concepts (64)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 5 | 2025 | 898 | 1.430 |
Why?
|
| T-Lymphocytes | 4 | 2025 | 1758 | 1.380 |
Why?
|
| Glypicans | 1 | 2024 | 39 | 0.880 |
Why?
|
| Interleukin-15 | 1 | 2024 | 96 | 0.850 |
Why?
|
| Hematologic Neoplasms | 2 | 2025 | 294 | 0.780 |
Why?
|
| Neoplasms | 4 | 2025 | 2953 | 0.730 |
Why?
|
| Sarcoma, Ewing | 1 | 2019 | 116 | 0.560 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 264 | 0.500 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2024 | 1192 | 0.460 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2019 | 461 | 0.460 |
Why?
|
| Patient Safety | 1 | 2019 | 438 | 0.440 |
Why?
|
| Genetic Therapy | 1 | 2019 | 720 | 0.430 |
Why?
|
| Catheter-Related Infections | 2 | 2024 | 137 | 0.360 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2025 | 499 | 0.290 |
Why?
|
| Graft vs Host Disease | 2 | 2023 | 621 | 0.290 |
Why?
|
| Gangliosides | 1 | 2025 | 73 | 0.220 |
Why?
|
| beta-Thalassemia | 1 | 2023 | 30 | 0.210 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 47 | 0.200 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 52 | 0.200 |
Why?
|
| Interleukin-6 | 1 | 2024 | 436 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 141 | 0.190 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 146 | 0.190 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2022 | 67 | 0.180 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 241 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 356 | 0.170 |
Why?
|
| Neuroblastoma | 1 | 2025 | 550 | 0.160 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 67 | 0.150 |
Why?
|
| Cross Infection | 1 | 2022 | 343 | 0.150 |
Why?
|
| Child | 9 | 2025 | 25758 | 0.150 |
Why?
|
| Humans | 13 | 2025 | 132105 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2024 | 698 | 0.140 |
Why?
|
| Sepsis | 1 | 2022 | 515 | 0.140 |
Why?
|
| Forecasting | 1 | 2019 | 372 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 5399 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 816 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2024 | 5150 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 757 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2025 | 17374 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2059 | 0.090 |
Why?
|
| Genomics | 1 | 2019 | 1651 | 0.090 |
Why?
|
| Male | 4 | 2025 | 64918 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2019 | 3714 | 0.080 |
Why?
|
| Female | 4 | 2025 | 70680 | 0.080 |
Why?
|
| Infant | 4 | 2025 | 13039 | 0.070 |
Why?
|
| Child, Preschool | 4 | 2025 | 14718 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2025 | 13017 | 0.070 |
Why?
|
| Oral Health | 1 | 2024 | 27 | 0.060 |
Why?
|
| Middle Aged | 1 | 2024 | 28936 | 0.050 |
Why?
|
| Alemtuzumab | 1 | 2023 | 88 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 43 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 150 | 0.050 |
Why?
|
| Chlorhexidine | 1 | 2022 | 47 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2023 | 300 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 648 | 0.050 |
Why?
|
| Adolescent | 3 | 2025 | 20532 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2025 | 675 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 105 | 0.050 |
Why?
|
| Adult | 1 | 2022 | 31557 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 425 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1454 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2022 | 617 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 482 | 0.040 |
Why?
|
| Prognosis | 1 | 2025 | 5008 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2023 | 6530 | 0.020 |
Why?
|